Metric Deep Dive: Understanding DXC Technology Co (DXC) Through its Ratios

Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.

After finishing at $19.79 in the prior trading day, DXC Technology Co (NYSE: DXC) closed at $19.58, down -1.06%. In other words, the price has decreased by -$1.06 from its previous closing price. On the day, 1.23 million shares were traded. DXC stock price reached its highest trading level at $19.92 during the session, while it also had its lowest trading level at $19.545.

Ratios:

Our goal is to gain a better understanding of DXC by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.12 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 2.76. For the most recent quarter (mrq), Quick Ratio is recorded 1.11 and its Current Ratio is at 1.11. In the meantime, Its Debt-to-Equity ratio is 1.73 whereas as Long-Term Debt/Eq ratio is at 1.42.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Guggenheim on March 19, 2024, initiated with a Neutral rating and assigned the stock a target price of $22.

On January 24, 2024, JP Morgan Downgraded its rating to Underweight which previously was Neutral and also lowered its target price recommendation from $27 to $24.

Citigroup Downgraded its Neutral to Sell on January 17, 2024, whereas the target price for the stock was revised from $24 to $21.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 14 ’24 when Drumgoole Christopher sold 10,000 shares for $20.33 per share. The transaction valued at 203,267 led to the insider holds 214,682 shares of the business.

Voci Christopher Anthony sold 2,500 shares of DXC for $51,494 on Mar 14 ’24. The SVP, Controller and PAO now owns 70,851 shares after completing the transaction at $20.60 per share. On Mar 01 ’24, another insider, DECKELMAN WILLIAM L JR, who serves as the EVP & General Counsel of the company, sold 18,102 shares for $21.88 each. As a result, the insider received 396,072 and left with 106,704 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DXC now has a Market Capitalization of 3580614400 and an Enterprise Value of 7526607360. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.26 while its Price-to-Book (P/B) ratio in mrq is 1.17. Its current Enterprise Value per Revenue stands at 0.543 whereas that against EBITDA is 16.186.

Stock Price History:

Over the past 52 weeks, DXC has reached a high of $28.89, while it has fallen to a 52-week low of $18.61. The 50-Day Moving Average of the stock is -7.05%, while the 200-Day Moving Average is calculated to be -11.97%.

Shares Statistics:

The stock has traded on average 2.64M shares per day over the past 3-months and 1623030 shares per day over the last 10 days, according to various share statistics. A total of 214.72M shares are outstanding, with a floating share count of 180.26M. Insiders hold about 1.43% of the company’s shares, while institutions hold 97.73% stake in the company. Shares short for DXC as of 1711584000 were 15079202 with a Short Ratio of 5.71, compared to 1709164800 on 14669435. Therefore, it implies a Short% of Shares Outstanding of 15079202 and a Short% of Float of 9.7399995.

Dividends & Splits

The stock’s 5-year Average Dividend Yield is 1.62.

Earnings Estimates

The dynamic stock of DXC Technology Co (DXC) is currently attracting attention from ChromaDex Corporation analysts actively involved in rating its market status.The consensus estimate for the next quarter is $36.68, with high estimates of $134.30 and low estimates of $19.58.

Analysts are recommending an EPS of between $Healthcare and $Technology for the fiscal current year, implying an average EPS of $Utilities.

Most Popular

[the_ad id="945"]